Martin Reck, MD, PhD, on SCLC: Maintenance Therapy for Patients With Extensive-Stage Disease
IASLC 2020 World Conference on Lung Cancer in Singapore
Martin Reck, MD, PhD, of LungenClinic, discusses results from the IMpower133 study of carboplatin plus etoposide with or without atezolizumab in patients with untreated extensive-stage small cell lung cancer (Abstract OA11.06).
Prasad S. Adusumilli, MD, of Memorial Sloan Kettering Cancer Center, discusses ongoing CAR T-cell therapy clinical trials for solid tumors, the key determinants of success for developing this treatment, and some study results to date (Abstract PL03.05).
Roy S. Herbst, MD, PhD, of Yale University, discusses two key abstracts from the ADAURA trial: the use of osimertinib as adjuvant therapy for resected EGFR-mutated non–small cell lung cancer; and patient-reported outcomes, which showed a benefit in disease-free survival and maintenance of health-related quality of life in patients with resected stage IB to IIIA disease (Abstracts OA06.04 and OA06.03).
Silvia Novello, MD, PhD, of the University of Turin, discusses phase III results from the ITACA trial, which explored the notion of improving survival by customizing treatment and reducing toxicities for patients with completely resected stage II to IIIA non–small cell lung cancer (Abstract PS01.04).
Roy S. Herbst, MD, PhD, of Yale University, discusses results from the LUNG-MAP Master Protocol, which support the planned use of circulating tumor DNA for enrollment onto LUNG-MAP substudies, with a positive finding meriting inclusion in study; a negative finding, while considered inconclusive, requires the use of tissue samples (Abstract MA08.10).
Dean Fennell, FRCP, PhD, of the University of Leicester, discusses phase III results from the CONFIRM trial, which sought a standard immunotherapy treatment to improve overall survival for patients with mesothelioma who have relapsed after taking pemetrexed and cisplatin. Globally, the incidence of mesothelioma is on the rise; in the United Kingdom alone, it has gone up nearly 500% since the 1970s (Abstract PS01.11).